Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Therapy Using Lenalidomide in Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No signs of progression after transplant~* Effective contraception if necessary (oral contraception for females and barrier methods of contraception for sexually active males)~* No active severe infection~* Satisfactory restoration of the haematological parameters defined by: PN \>1,000/mm3 and Platelets \> 75,000/mm3~* Bilirubin \< 35 umol/l and GOT/GPT/PAL\<3N~* Creatinine \< 160 umol/l.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- placebo group (Type: PLACEBO_COMPARATOR): Administration of oral placebo
- lenalidomide group (Type: EXPERIMENTAL): Administration of lenalidomide

Based on this trial design, predict the completion outcome and termination type (if applicable).